Bausch Considers Proposal For COVID-19 Drug: Lumify Eye Drops Inactivate Virus In Lab Tests
Bausch Health says its Lumify OTC redness reliever drops showed "complete inactivation" of COVID-19 in time-kill tests, with preservative compound benzalkonium chloride apparently the key reason. The in vitro findings prompted it to consider discussions with regulatory agencies on proposing a remedy for the virus.
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Manufacturers considering use of the popular 99.99% germ-kill claim on hand sanitizer products should consult the Office of Compliance, said Division of Nonprescription Drug Products director Theresa Michele during a recent industry workshop. “Be very, very cautious about the claims you are making,” she said.
Recent personal-care product launches show companies innovating in emerging frontiers and hazily regulated territory with probiotic oral care, over-the-counter fungal nail care and nasal antiseptic care. Elsewhere, sensitive skin specialist Cetaphil introduces ultra-moisturizing products, and Nestle Health Sciences’ Atrium Innovations launches a line of nutritional supplements for skin, hair and nail health.